Colgate-Palmolive Company
CL
$95.29
+2.29%
Colgate-Palmolive is a 200-year-old global consumer staples manufacturer whose portfolio spans oral care (its namesake toothpaste and toothbrush franchise accounts for more than 40% of sales), personal care (shampoos, shower gels, deodorants), home care products, and the Hill's Pet Nutrition specialty pet food business, which contributes roughly a quarter of revenue and is sold primarily through veterinarians and specialty retailers. The company is a textbook defensive compounder: it holds the global leadership position in oral care, generates about 70% of sales outside the US with nearly half from emerging markets, and competes on brand equity, shelf space, and distribution scale rather than on innovation cycles. The current investor debate centers on whether Colgate can sustain its recent organic growth reacceleration — Q2 2026 revenue rose 4.9% year over year to $5.36 billion — while absorbing input-cost and foreign-exchange pressure, and on the durability of the rotation into defensive staples that has driven the stock's 21% YTD gain. Management's pricing power, the Hill's premiumization story, and a 2.85% dividend yield are the pillars bulls cite, while bears point to a stretched multiple, a 158% debt-to-equity ratio, and the risk that defensive leadership unwinds if growth-oriented sectors regain favor.…
CL
Colgate-Palmolive Company
$95.29
Investment Opinion: Should I buy CL Today?
Rating: Hold. The core thesis is that Colgate is a high-quality defensive compounder with a 61.5% gross margin, $3.86 billion FCF, and a 2.85% dividend yield, but the stock has already rallied 21% YTD and trades at 23x forward earnings, leaving only 4.4% upside to the $98.15 consensus target. The analyst consensus is 'buy' (mean 2.05), but the modest target gap suggests the easy money has been made.
Supporting evidence: revenue grew 4.91% YoY to $5.361 billion in Q2 2026; gross margin expanded to 61.48% from 60.06%; TTM FCF is $3.858 billion; and the forward PE of 23.01x compares to a trailing PE of 29.93x, implying 23% EPS growth. The 2.85% dividend yield and 85.5% payout ratio are sustainable given FCF, and ROE of 39.48% demonstrates strong returns on capital. However, the EV/EBITDA of 14.62x is above the historical 12-13x norm, and the PS ratio of 3.14x is moderate for the sector.
Risks and conditions: the biggest risks are a rotation out of defensives, margin compression from SG&A and FX, and leverage (D/E 158.4%, current ratio 0.833). This Hold would upgrade to Buy if the stock pulls back to the $87 analyst low target (implying 20x forward PE) or if organic growth accelerates above 6% with margin expansion. It would downgrade to Sell if revenue growth decelerates below 3% or if operating margin falls below 18%. Valuation verdict: fairly valued to slightly overvalued relative to history and peers, with the premium justified only by continued defensive flows.
Sign up to view all
CL 12-Month Price Forecast
CL is a high-quality defensive compounder that has already priced in much of its near-term good news, with the stock up 21% YTD and trading at 23x forward earnings. The base case (55% probability) targets $95-$100, aligned with the analyst average of $98.15, as earnings growth of 5-6% offsets multiple compression risk. The bull case (25%) relies on continued defensive rotation and margin expansion toward $110, while the bear case (20%) sees a rotation-driven de-rating to $87 or lower. I would upgrade to bullish if the stock pulls back to $87 (20x forward) or if organic growth accelerates above 6%; I would downgrade to bearish if operating margin falls below 18% or if defensive flows reverse sharply.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Colgate-Palmolive Company's 12-month outlook, with a consensus price target around $98.15 and implied upside of +3.0% versus the current price.
Average Target
$98.15
0 analysts
Implied Upside
+3.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$87 - $110
Analyst target range
Coverage is broad and constructive: 20 analysts cover Colgate with a consensus recommendation of "buy" (mean rating 2.05 on a scale where lower is more bullish) and an average target price of $98.15. Against the current price of $94.04, that implies roughly +4.4% upside to the consensus target — a modest gap that suggests the stock has largely caught up to analyst expectations after its 21% YTD run. The distribution of recent institutional ratings is overwhelmingly positive, with Piper Sandler, RBC Capital, JP Morgan, UBS, and Evercore ISI all maintaining Overweight/Buy/Outperform stances through September 2026, and only TD Cowen and Barclays sitting at Hold/Equal Weight — a bullish tilt with a small skeptical fringe.
The target range of $87.00 to $110.00 is moderately wide (about 26% from low to high), signaling meaningful dispersion in assumptions. The $110 high target implies roughly 17% upside and likely assumes continued defensive-rotation flows, margin expansion from pricing and Hill's mix, and multiple expansion toward the upper end of the staples band; the $87 low target implies about 7.5% downside and likely prices in margin compression from input costs or FX, a rotation back out of defensives, and a de-rating toward the low-20s forward PE. Consensus EPS estimates of $4.78 (range $4.67-$4.86) and revenue of $24.19 billion (range $23.76-$24.48 billion) are tightly clustered, indicating high confidence in the near-term earnings trajectory even if the multiple is contested. With the average target only 4.4% above the current price and the stock having just pulled back 3.4% from a spike high, the risk/reward is balanced — analysts are not chasing the stock higher, and the wide $87-$110 spread means position sizing should account for the possibility that the defensive trade unwinds.
Drowning in data?
Find the real signal!
Bulls vs Bears: CL Investment Factors
The bull case currently has stronger evidence: CL's 21% YTD outperformance, 61.5% gross margin, $3.86 billion FCF, and consensus buy rating are tangible, while the bear case rests largely on valuation and the sustainability of the defensive rotation. The single most important tension is whether the market's premium multiple (23x forward) can be justified by margin expansion and continued defensive flows, or whether a rotation back to growth sectors triggers a de-rating toward the low-20s forward PE. If the defensive trade holds and Hill's premiumization accelerates, the stock can grind toward the $110 high target; if rotation reverses, the $87 low target becomes the magnet.
Bullish
- Defensive rotation driving outperformance: CL has gained 21.05% YTD versus the S&P 500's 11.45%, a 9.6 percentage point relative strength spread, and 9.44% in the past month alone versus a 1.02% decline for the index. With a beta of just 0.322, the stock offers roughly one-third the market's volatility while still delivering superior returns, making it a magnet for risk-budgeted and defensive portfolios.
- Steady organic growth with Hill's premiumization: Q2 2026 revenue rose 4.91% year over year to $5.361 billion, with no quarter in the trailing four below $5.13 billion. Hill's Pet Nutrition contributes $1.195 billion, or roughly 22% of quarterly sales, and remains the higher-growth, higher-margin engine that supports the premiumization narrative.
- Best-in-class gross margins: Gross margin of 61.48% in Q2 2026 is up from 60.06% a year earlier and 60.59% in Q1 2026, demonstrating pricing power and cost discipline. A 61% gross margin is exceptional for household products and provides a buffer against input-cost inflation.
- Strong free cash flow and shareholder returns: TTM free cash flow is $3.858 billion, with Q2 2026 operating cash flow of $995 million against just $128 million of capex. The company returned $462 million in dividends and $291 million in buybacks in the quarter, and the 2.85% dividend yield is comfortably covered by FCF despite an 85.5% payout ratio.
Bearish
- Rich valuation for low growth: At 29.93x trailing and 23.01x forward earnings, CL trades at the upper end of the staples range where peers typically sit in the high-teens to low-20s forward. A 23x forward multiple on sub-5% revenue growth requires either margin expansion or continued defensive-rotation flows to be sustained.
- Elevated leverage and thin liquidity: Debt-to-equity stands at 158.4% and the current ratio is a thin 0.833, reflecting a capital structure built on buybacks and dividends rather than debt reduction. While FCF of $3.858 billion covers obligations, the limited liquidity cushion leaves little room for error if cash flow dips.
- Margin pressure from SG&A and other expenses: Operating margin fell to 18.95% in Q2 2026 from 21.14% a year earlier, driven by higher SG&A of $2.13 billion and a $66 million swing in other income/expense. The Q4 2025 net loss of $37 million from a $970 million other-expense charge shows how non-operating items can distort earnings.
- Defensive trade may unwind: The stock's 21% YTD gain is largely attributable to rotation into defensive staples, as highlighted by recent commentary on the rotation trade. If growth-oriented sectors regain favor, CL could see multiple compression toward its historical 12-13x EV/EBITDA norm from the current 14.62x.
CL Technical Analysis
Colgate is in a sustained uptrend that has recently accelerated into a breakout. The stock is up 19.89% over the past year and 21.05% year to date, and at $94.04 it sits at roughly 78.6% of its 52-week range of $74.55 to $99.33 — closer to the highs than the lows, which signals momentum leadership rather than deep value. The 52-week high of $99.33 is only about 5.6% above the current price, meaning the stock is pressing against resistance after a strong run rather than consolidating in the middle of its band.
Short-term momentum is decisively positive and has re-accelerated: the stock gained 9.44% over the past month versus a 1.02% decline for the S&P 500, a relative strength spread of 10.46 percentage points, and added 3.63% over three months against the index's 2.85%. That one-month surge is far stronger than the 19.89% twelve-month gain would imply on a pro-rata basis, indicating an accelerating rather than decelerating trend — the October move from roughly $84 to a $97.39 close on October 22 (the highest print in the dataset) before a 3.44% pullback to $94.04 on October 23 looks like a sharp extension followed by a one-day shakeout. Volume of 4.74 million shares on the latest session is unremarkable for a mega-cap staple, so the pullback lacks the distribution signature of a trend reversal, though the single-day 3.4% drop after a parabolic run warrants monitoring for follow-through selling.
Key technical levels are well defined: support sits at the 52-week low of $74.55, with intermediate support around the $84-$86 zone that contained the September-October consolidation, while resistance is the 52-week high of $99.33, just above the October 22 spike high of $97.39. A clean breakout above $99.33 would confirm the uptrend and likely invite momentum and defensive-rotation flows, whereas a breakdown below $84 would break the higher-lows structure and signal that the October spike was an exhaustion move. Volatility is exceptionally low — beta of 0.322 means the stock moves roughly one-third as much as the market, and the maximum drawdown of -17.48% over the period is modest for an equity — which supports larger position sizing for risk-budgeted portfolios but also means the 3.4% single-day drop is a statistically large move (over 10x its beta-implied daily expectation) that deserves attention.
Beta
0.32
0.32x market volatility
Max Drawdown
-17.5%
Largest decline past year
52-Week Range
$75-$99
Price range past year
Annual Return
+24.5%
Cumulative gain past year
| Period | CL Return | S&P 500 |
|---|---|---|
| 1m | +11.7% | -0.9% |
| 3m | +4.4% | +1.2% |
| 6m | +9.2% | +4.9% |
| 1y | +24.5% | +11.2% |
| ytd | +22.7% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CL Fundamental Analysis
Revenue is growing at a steady, modest clip consistent with a mature staples franchise. Q2 2026 revenue of $5.361 billion rose 4.91% year over year from $5.110 billion in Q2 2025, and the trailing four quarters ($5.361B + $5.324B + $5.230B + $5.131B = $21.05 billion) show a consistent sequential cadence with no quarter below $5.13 billion. Segment data shows Oral, Personal and Home Care at $4.166 billion and Hill's Pet Nutrition at $1.195 billion, meaning the pet business is roughly 22% of the quarter — Hill's remains the higher-growth, higher-margin engine while the core care portfolio provides the pricing-driven base. The trajectory implies low-to-mid single-digit organic growth, which is adequate for a defensive compounder but leaves little room for multiple expansion without margin or buyback support.
Profitability is solid and margins are holding at healthy staples levels. Q2 2026 net income was $693 million on a 12.93% net margin, with gross margin of 61.48% (gross profit of $3.296 billion) and operating margin of 18.95% ($1.016 billion operating income). Gross margin has been remarkably stable — 61.48% in Q2 2026 versus 60.06% in Q2 2025 and 60.59% in Q1 2026 — while the operating margin of 18.95% is below the 21.14% posted in Q2 2025, reflecting higher SG&A of $2.13 billion and a $66 million swing in other income/expense. The Q4 2025 net loss of $37 million (EPS -$0.046) was driven by a $970 million other-expense charge, not operating deterioration, since that quarter still produced $1.077 billion of operating income — a one-off that distorts trailing metrics but not the underlying earnings power.
Balance-sheet leverage is the principal fundamental risk. Debt-to-equity stands at 158.4%, the current ratio is a thin 0.833, and the historical debt ratio of roughly 0.47-0.49 of assets reflects a capital structure built on buybacks and dividends rather than debt reduction. Cash generation remains robust: TTM free cash flow is $3.858 billion, Q2 2026 operating cash flow was $995 million against $128 million of capex (FCF of $867 million), and the company returned $462 million in dividends plus $291 million in buybacks in the quarter — a payout ratio of 85.5% that is high but covered by FCF. ROE of 39.48% and ROA of 15.84% are flattered by leverage but still demonstrate strong returns on capital; the key question is whether FCF of roughly $3.9 billion comfortably services the debt load and dividend, and at a 2.85% yield with a 15.2x price-to-cash-flow multiple, the answer is yes, though the thin current ratio leaves limited liquidity cushion.
Quarterly Revenue
$5.4B
2026-06
Revenue YoY Growth
+4.9%
YoY Comparison
Gross Margin
61.5%
Latest Quarter
Free Cash Flow
$3.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CL Overvalued?
Because Colgate is profitable (Q2 2026 net income of $693 million; TTM EPS positive), the PE ratio is the appropriate primary metric. The stock trades at 29.93x trailing earnings but only 23.01x forward earnings, a 23% compression that implies the market expects meaningful EPS growth — consistent with the consensus 2026 EPS estimate of $4.78 versus the current run-rate. The trailing PE of 29.93x on a 12.93% net margin and 4.9% revenue growth is a rich multiple for a low-growth staples business, and the PEG ratio of -1.19 is not meaningful given the distorted trailing earnings base from the Q4 2025 charge.
Relative to the household and personal products industry, Colgate screens as a premium defensive asset. Its PS ratio of 3.14x and EV/sales of 4.01x are moderate for the sector, but the EV/EBITDA of 14.62x and forward PE of 23.0x sit at the upper end of the staples range, where peers typically trade in the high-teens to low-20s on forward earnings. The premium is partly justified by Colgate's category leadership, 61% gross margin, and 2.85% dividend yield, but a 23x forward multiple for a company growing revenue at under 5% requires either margin expansion or continued defensive-rotation flows to be sustained — the 14.6x EV/EBITDA versus a historical norm nearer 12-13x suggests the market is already paying up.
Historically, Colgate's own valuation band has been wide and volatile on a reported basis: quarterly PE ratios in the historical data range from about 21.96x (Q3 2025) to 41.75x (Q1 2023), with the current 29.93x trailing sitting in the upper-middle of that range. On price-to-sales, the current 3.14x compares with historical quarterly readings of 12.16x-16.87x in the provided series — a discrepancy that reflects a change in the share-count/market-cap basis in the data rather than a true re-rating, so the PS comparison should be treated with caution. The more reliable read is the PE: at roughly 30x trailing and 23x forward, the stock is priced for optimism, and the 2.85% dividend yield is below its own historical 4-7% range shown in the data, reinforcing that the market is paying a premium for defensive growth.
PE
29.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 21x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on leverage and margin pressure. Debt-to-equity of 158.4% and a current ratio of 0.833 leave limited liquidity cushion, while the 85.5% payout ratio means dividends and buybacks consume most free cash flow. Operating margin fell to 18.95% in Q2 2026 from 21.14% a year earlier due to higher SG&A of $2.13 billion and a $66 million swing in other income/expense, and the Q4 2025 net loss of $37 million from a $970 million charge shows earnings volatility from non-operating items. Revenue concentration in oral care (over 40% of sales) and international markets (70% of sales, nearly half from emerging markets) adds FX and geopolitical exposure.
Market and competitive risks include valuation compression and sector rotation. At 23.01x forward earnings and 14.62x EV/EBITDA, CL trades at a premium to its historical 12-13x EV/EBITDA norm, leaving room for de-rating if defensive flows reverse. The stock's beta of 0.322 means it is relatively insulated from broad market swings, but that also means it may lag if growth sectors rally. Competitive threats from private-label and smaller brands in oral care, plus potential pricing pushback in emerging markets, could pressure the 61.48% gross margin. Recent news highlighting the rotation trade warns that valuation disparities favoring defensives may be unsustainable.
Worst-case scenario: a rotation out of defensives combined with margin compression from input costs and FX would likely drive the stock toward the analyst low target of $87, a 7.5% decline from $94.04, and potentially to the 52-week low of $74.55, a 20.7% decline. The maximum drawdown over the period was -17.48%, so a drop to the 52-week low would be consistent with historical stress. In this scenario, an investor could lose 7.5% to 20.7% from the current price, with the $87 level as the first stop and $74.55 as the extreme downside.
FAQ
The key risks, ranked by severity: (1) Valuation compression — at 23x forward earnings, a rotation out of defensives could drive the stock to $87 or lower; (2) Leverage — debt-to-equity of 158.4% and a current ratio of 0.833 leave limited liquidity cushion; (3) Margin pressure — operating margin fell to 18.95% from 21.14% on higher SG&A and other expenses; (4) International exposure — 70% of sales outside the US, nearly half from emerging markets, exposes CL to FX and geopolitical risk. The 85.5% payout ratio also limits financial flexibility if FCF declines.
The 12-month forecast has three scenarios: bull case (25% probability) targets $105-$110 on continued defensive rotation and margin expansion; base case (55%) targets $95-$100, aligned with the $98.15 analyst average, on 5-6% earnings growth; bear case (20%) targets $74.55-$87 on a rotation-driven de-rating. The base case is most likely, assuming organic growth of 4-5% and stable gross margins around 61%. The key assumption is that defensive flows remain supportive and the multiple holds near 23x forward earnings.
CL appears fairly valued to slightly overvalued. The trailing PE of 29.93x and forward PE of 23.01x sit at the upper end of the staples range, where peers trade in the high-teens to low-20s forward. The EV/EBITDA of 14.62x is above the historical norm of 12-13x, and the 2.85% dividend yield is below its own historical 4-7% range, indicating the market is paying a premium for defensive growth. The valuation implies the market expects continued margin expansion and defensive rotation flows; without those, the stock could de-rate toward 20x forward earnings, or roughly $87.
CL is a good buy for defensive, income-oriented investors, but the risk/reward is balanced at $94.04. The stock trades at 23.01x forward earnings with only 4.4% upside to the $98.15 consensus target, and the 2.85% dividend yield is below its historical 4-7% range. The biggest downside risk is a rotation out of defensives, which could push shares to the $87 analyst low target (7.5% downside) or the $74.55 52-week low (20.7% downside). For long-term holders seeking low volatility (beta 0.322) and stable FCF of $3.86 billion, CL is a solid core holding, but new buyers may want to wait for a pullback toward $87 for better margin of safety.
CL is best suited for long-term investment, with a suggested minimum holding period of 2-3 years. Its beta of 0.322 and maximum drawdown of -17.48% indicate low volatility, and the 2.85% dividend yield provides steady income. However, the stock's 21% YTD rally and 23x forward multiple limit near-term upside, making short-term trading less attractive. Long-term investors can benefit from the defensive compounder profile, 61.5% gross margin, and $3.86 billion FCF, but should monitor margin trends and defensive rotation flows for signs of de-rating.